Vapotherm Inc (NYSE:VAPO) CEO Joseph Army bought 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average price of $10.00 per share, with a total value of $100,000.00.
Joseph Army also recently made the following trade(s):
- On Friday, August 2nd, Joseph Army bought 15,000 shares of Vapotherm stock. The stock was purchased at an average price of $14.28 per share, with a total value of $214,200.00.
Shares of VAPO stock opened at $8.70 on Thursday. The firm has a 50 day moving average price of $13.80 and a two-hundred day moving average price of $17.74. The company has a quick ratio of 4.34, a current ratio of 5.22 and a debt-to-equity ratio of 1.42. The company has a market capitalization of $166.24 million and a PE ratio of -0.63. Vapotherm Inc has a 12-month low of $8.30 and a 12-month high of $24.63.
A number of hedge funds have recently modified their holdings of VAPO. Deutsche Bank AG bought a new position in shares of Vapotherm during the fourth quarter worth approximately $121,000. Marshall Wace North America L.P. bought a new position in shares of Vapotherm during the first quarter worth approximately $161,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Vapotherm by 10.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 12,488 shares of the company’s stock worth $288,000 after purchasing an additional 1,151 shares during the period. Monashee Investment Management LLC bought a new position in shares of Vapotherm during the second quarter worth approximately $484,000. Finally, Arnhold LLC increased its holdings in shares of Vapotherm by 123.9% during the first quarter. Arnhold LLC now owns 25,434 shares of the company’s stock worth $500,000 after purchasing an additional 14,075 shares during the period. Hedge funds and other institutional investors own 50.85% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Vapotherm from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Friday, August 2nd. Five equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $23.67.
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Featured Article: How is a price target determined?
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.